MeSH term
Frequency | Condition_Probility | Female | 4 | 0.0 |
Humans | 54 | 0.0 |
Drug Interactions | 3 | 0.0 |
Animals | 16 | 0.0 |
Base Sequence | 10 | 0.0 |
Cell Line | 21 | 0.0 |
Hela Cells | 6 | 0.0 |
Mice | 4 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Proteins/genetics/*metabolism | 9 | 1.0 |
Research Support, Non-U.S. Gov't | 40 | 0.0 |
Cohort Studies | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 28 | 0.0 |
United States | 2 | 0.0 |
Aged | 2 | 0.0 |
Male | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Amino Acid Sequence | 11 | 0.0 |
Blotting, Western | 3 | 0.0 |
Gene Deletion | 3 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Binding | 5 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Virus Replication/physiology | 3 | 13.0 |
Zinc Fingers | 2 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Virus Replication | 10 | 1.0 |
Apolipoproteins B/*genetics | 2 | 1.0 |
Cells, Cultured | 2 | 0.0 |
HIV-1/genetics | 2 | 3.0 |
Transfection | 12 | 0.0 |
Proteins/genetics/physiology | 2 | 3.0 |
Antiviral Agents/metabolism | 2 | 22.0 |
Comparative Study | 4 | 0.0 |
Cytidine Deaminase/*metabolism | 4 | 36.0 |
DNA Primers | 4 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Mutagenesis/*genetics | 4 | 15.0 |
Point Mutation/genetics | 3 | 1.0 |
Sequence Alignment | 2 | 0.0 |
Virus Inhibitors/*physiology | 3 | 25.0 |
Proteins/*physiology | 3 | 1.0 |
Species Specificity | 4 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Gene Products, gag/*metabolism | 2 | 15.0 |
Gene Products, vif/metabolism | 3 | 60.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
HIV-1/*metabolism | 5 | 2.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Nucleocapsid/metabolism | 2 | 66.0 |
RNA/metabolism | 2 | 0.0 |
Virus Assembly | 2 | 7.0 |
HIV-1/*physiology | 2 | 0.0 |
RNA, Viral/metabolism | 4 | 4.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
HIV/genetics | 2 | 5.0 |
Mutation/genetics | 2 | 0.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Gene Products, vif/*metabolism | 10 | 100.0 |
HIV-1/pathogenicity/*physiology | 4 | 14.0 |
Protein Binding/physiology | 2 | 0.0 |
Proteins/*metabolism | 10 | 1.0 |
Virus Replication/*physiology | 3 | 5.0 |
*Virus Replication | 4 | 1.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Gene Products, vif/physiology | 2 | 100.0 |
Immunosorbent Techniques | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Gene Products, vif/genetics/*metabolism | 5 | 83.0 |
Immunoprecipitation | 2 | 0.0 |
Mutation | 7 | 0.0 |
Gene Products, vif/*physiology | 2 | 100.0 |
HIV-1/genetics/*physiology | 3 | 2.0 |
Substrate Specificity | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Proteins/*genetics/*metabolism | 2 | 2.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Deamination | 2 | 22.0 |
HIV Infections/virology | 2 | 2.0 |
Protein Biosynthesis | 2 | 0.0 |
Ubiquitin/*metabolism | 4 | 2.0 |
*Amino Acid Substitution | 2 | 2.0 |
Binding Sites | 2 | 0.0 |
Lentivirus/metabolism | 2 | 50.0 |
Cercopithecus aethiops | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
*Virus Assembly | 4 | 16.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
DNA, Viral/*biosynthesis/*genetics | 2 | 100.0 |
Gene Products, vif/deficiency/genetics/metabolism | 2 | 100.0 |
Gene Products, gag/physiology | 2 | 100.0 |
